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Abstract of dissertation 
Background: In the 21st century the advancements of science have broaden our understanding 
about the pathology, treatment, drug resistance, evolutional phylogeny, population structure 
and transmission dynamics of the TB bacilli. However, these advancements were not sufficient 
enough to halt the TB epidemic in many Sub Saharan countries. Especially, the emergence of 
multi drug resistance tuberculosis has posed a significant threat to global TB control. In 
Ethiopia, TB is one of the three top killer infectious diseases. It is still the major problem in 
some pocket geographical areas, refugee camps and prisons. TB in prison was not receiving 
enough attention in the past years, considering the role prisons are playing in ongoing local TB 
epidemics. As a result, the burden of TB in Ethiopian prisons was largely obscured. 
Objective: To determine the epidemiology and risk factors of TB in prisons, together with the 
population structure, transmission dynamics and drug resistance profile of Mycobacterium 
tuberculosis complex isolates in Ethiopian prisons. 
Methodology: A two phases cross sectional study was done between Jan, 2013 and May, 
2015. Prisons and communities living in south western, southern and Eastern part of the 
country were included. In the first phase 13 zonal prisons from Oromia, SNNPRS and Harari 
were included to determine the magnitude and identify the risk factors for TB in prison. In phase 
two, all M.tuberculosis complex (MTBC) strains isolated in prison and additional 106 control 
MTBC strains collected from newly diagnosed smear positive TB patients attending selected 
hospitals at regional states of Oromia, South Nations and Nationalities Peoples, Harari, Somali 
and  Dire Dawa city administration were included. 
Result: A total of 15,495 inmates were screened by WHO TB screening criteria and 765 
suspects were identified. The prevalence of tuberculosis in Ethiopian prison was 458/100.000 
inmates. Alcohol consumption, contact with TB patients at home, window availability in prison 
cells had contributed for the observed prevalence. Furthermore, a total of 11 different lineages/ 
sub-lineages were identified by combined technique of MIRU-VNTR and spoligotyping. The 
clustering rate of isolates from prison and community was 28.57% and 31.82% respectively, 
with some strains from prison and communities sharing the same cluster. The predominant 
genotype was the recently described Ethiopian_H37Rv like with equal distribution between the 
prison and the community isolates. The MDR prevalence in the community was 2.27% with no 
difference with that of prison.  
Conclusion: The prevalence of tuberculosis in Ethiopian prisons is more than twice higher than 
the population estimate. The diverse population structure and low clustering of MTBC observed 
in this study has indicated that most of the TB cases in prison and communities were resulted 
from reactivation of remote infection. The magnitude of MDR in prison as well as community is 
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very worrisome. Hence, The TB control strategy in Ethiopia should be tailored to address MDR 
and latent infection. 
Key words; Tuberculosis, prison, population structure, drug resistance, Jimma university 
Contribution of this work to the research area:  
This paper is the first paper to describe the population structure and drug resistance profile of 
M. tuberculosis in Ethiopia prisons which was unknown before. The observed low clustering 
rate combined with the strong association of TB with previous contact with TB patient at home 
and the observed shared cluster between prison isolate and community isolates clearly 
indicated the area of focus to control TB in Ethiopia. 
1. Introduction 
1.1. Tuberculosis in human history 
Tuberculosis (TB) is used to be known by different names such as consumption, white plague, 
scrofula, King’s evil, lupus vulgaris, and phthisis (Hart et al., 1996). These names were given as 
an attempt to describe the disease condition or indicate how the disease was dreadful in the 
past (Ducati et al., 2006).  Even now in 21st century, tuberculosis is being continued to 
challenge the modern world and remained as one of the two top killer infectious diseases 
globally (Global tuberculosis report, 2015).  
Tuberculosis is an infectious disease caused by bacilli which belongs to the genus 
mycobacterium; specifically M.tuberculosis complex. According to recent estimations 
mycobacterium genera was originated more than 150 million years ago (Daniel, 2006; Hayman, 
1984).  There is growing evidence that indicates the existence of an early progenitor of M. 
tuberculosis in East Africa as early as 3 million years (Comas et al., 2015; Gutierrez et al., 
2005).  
Tuberculosis has a long history. It is one of the oldest diseases existed before the begging of 
ancient literatures (Daniel, 2006).  It has left its prints on human creativity and art (Hart et al., 
1996). However, more concrete evidence was observed from Egyptian 5400 years old 
Mummies. In this human archeological finding Pott’s deformities were reported (Crube et al., 
1998). Written evidence about TB was documented in ancient literatures from Andean (South 
America), China and Egypt as early as 4,000 years ago (Fusegaw et al., 2003; Zink et al., 2003; 
Baronn et al., 1996).  
Scientific concern for tuberculosis disease was actually started when Fracastero (1483-1553) 
inferred phthisis as an infectious disease (Hart et al., 1996). Later, Franciscus Sylvius (1614-
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1672) described the characteristics nodules from autopsy and he named it as tubercles (Hart et 
al., 1996).  During the golden era of microbiology Robert Koch has identified Mycobacterium 
tuberculosis in 1882 and demonstrated that TB is transmissible disease (Lakhtakia, 2014; 
Kaufmann, 2003). TB bacilli primarily causes pulmonary tuberculosis which comprises more 
than four fifth of TB cases seen in the world (Global tuberculosis report, 2015). MTBC can also 
disseminate to any part of the body and causes extra pulmonary TB (Ravigloin et al., 2012). 
The most common ones are pleural, lymph node, bones and joints, CNS and miliary 
tuberculosis (Herath et al., 2014; Ravigloin et al., 2012).   
1.2. Classification of  M. tuberculosis or the M. tuberculosis complex 
Tuberculosis is caused by a number of related groups of bacteria collectively known as 
Mycobacterium tuberculosis complex (MTBC) (Forrellad et al., 2013). The complex includes a 
total of six to seven species grouped under the genus mycobacterium (M .tuberculosis, M. 
bovis, M. africanum, M. Microtti, M. pinnipedii, M. cannetti and M. caprae) (Forrellad et al., 
2013). These species are genetically similar to each other sharing 99.9% DNA sequence 
identity in their chromosome but differs in primary host range and geographical distribution 
(Brites and Gagneux, 2015; Forrellad et al., 2013; Asiimwe et al., 2008).  
1.3. Genotyping of M.tuberculosis complex  
The discovery of molecular typing techniques has revolutionized the field of mycobacteriology 
and enabled to study of tuberculosis effectively. It has contributed significantly for the control 
and prevention of the disease. In the last decades, a large number of different molecular 
methods have been developed. These molecular methods discriminate the pathogen at the 
genus, species, and subspecies level (Ali et al., 2014).  
Molecular strain typing (genotyping) have been further used to understand TB global 
distribution (Middlekoop et al., 2015). Genotyping of MTBC is becoming a vital tool in TB 
epidemiology through provision of  vital information in relation to transmission dynamics , 
differentiating reactivation versus exogenous re infection, outbreak investigation, and mapping 
of the  geographical spread of successful clones, including multi-drug-resistant strains 
(Middlekoop et al., 2015;Ali et al., 2014; Gupta et al.,2014;Tessema et al., 13).    
In population based studies isolates that share the same genotype are considered as clusters 
and assumed epidemiologically linked (Barletta et al., 2015; Kato-Maeda et al., 2011). On the 
other hand, isolates of unique genotypes not shared by any other isolates within the population 
are considered as epidemiologically unrelated and resulted from reactivation of latent remote 
infection (Barletta et al., 2015; Kato-Maeda et al., 2011). This is only true by the assumption 
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that most of the peoples infected with MTBC will develop active form of the disease within the 
first 2-5 years (Barletta et al., 2015; Kato-Maeda et al., 2011).  
So far several robust methods have been developed to depict the global population structure of 
tuberculosis. In line with this, Restriction-fragment length polymorphism (RFLP) analysis (Van 
Embden et al., 1993),  Spoligotyping (Kamerbeek et al., 1997) and Mycobacterial Interspersed 
Repetitive Unit-Variable Number Tandem Repeats (MIRU-VNTRs) typing (Supply et al,. 2006; 
Kamerbeek et al., 1997) targeting different genes (DNA markers) to identify genotypes precisely 
were well described (Kato-Maeda et al., 2011). Accordingly, the global population structure of 
M. tuberculosis is defined in to seven phylogeographical lineages and 41 sub lineages (Figure 
1) (Brites et al., 2015;Barletta et al., 2015; Yang et al., 2015;Hill et al., 2012).   
 
 
Figure 1. Pictorial representation of phylogenic diversity of the seven M.tuberculosis complex 
lineages with their global geographical distribution; lineage 2, 3 and 4 are modern lineages with 
TbD1 deletion Adopted from (Coscolla and Gagneux, 2014) 
In our study, the isolated M.tuberculosis strains were analyzed at Research Center Borstel by 
using MIRU-VNTR typing customized kits (Genoscreen, Lilli, France). Basic strain classification. 
MLVA MTBC 15-9 nomenclature assignment was also done using the MIRU-VNTRplus 
database.  
1.4. Pathogenecity of tuberculosis 
Mycobacterium tuberculosis is transmitted by small airborne droplets generated from patients 
with pulmonary or laryngeal tuberculosis whenever they cough, sneeze, talk, or sing (Raviglion 
9 
 
et al., 2012). The diameter of the droplets generated should be small enough in size (1-5 µm) to 
reach deep into the lower respiratory tract as well as to remain suspended in the air (Riley et 
al., 1995; Wells, 1955). It is estimated that there might be as many as 3000 droplet nuclei 
released during a single cough (Maher et al., 1998). Droplets of larger size are efficiently 
excluded from the lower respiratory tract by the physical barriers of the nasopharynx and upper 
respiratory tract (Diamond et al., 1991).  
Mycobacterium tuberculosis has evolved to cause infection in many, yet causing disease in few. 
This is demonstrated by the observed high TB infection rate with relatively low active TB 
disease prevalence seen globally. According to the WHO estimation 1/3 of the world’s 
population harbors the bacilli.  Nevertheless, only 2-23% of these are expected to develop 
disease during their life time (Ling and Flynn, 2015; Barry et al., 2009: Parrish et al., 1998). The 
probability of M. tuberculosis transmission is also associated with the duration and intensity of 
exposure, conditions of the shared environment, virulence feature of the infecting 
M.tuberculosis strains and TB index case related factors like sputum smear positivity (Dheda et 
al., 2010).  
It is estimated that TB patients with single pulmonary cavity can produce as many as 105–107 
bacteria per milliliter of sputum which resulted in smear positivity and infectiousness (Lau et al., 
2016; Raviglion et al., 2012). The World Health Organization (WHO) also described sputum 
smear-positive pulmonary tuberculosis patients as the main source of TB infection in the 
community (http://www.who.int/mediacentre/factsheets/fs104/en/index.html ). Furthermore, 
different literatures had documented the contribution of smear positive patients in TB 
transmission (Lau et al., 2016; Pagaoa et al., 2015; Marks et al., 2000).  
2. Treatment and drug resistance 
Tuberculosis is a curable disease. Combination of four drugs isoniazid (H), rifampicin (R), 
pyrazinamide (Z) and ethambutol (E) has been remained as the first-line treatment since 1994 
(Bass et al., 1994; Treatment of tuberculosis, 2009 
http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1 ). These 
anti TB drugs have been part of WHO-recommended tuberculosis treatment regimens since 
1980s (Treatment of tuberculosis, 2009 
http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1). The 
standard care of treatment for drug sensitive tuberculosis includes a combination of four drugs 
(RHZE) for at least 6 months (Bass et al., 1994).  However, M.tuberculosis strains which are 
resistant to first line anti TB drugs were emerged since 1990 (Fischl et al., 1992). The 
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therapeutic options for patients infected with MDR-TB are very limited, less effective and more 
toxic than first-line anti TB drugs (Caminero et al., 2010). 
3. Epidemiology of tuberculosis 
3.1. Global Epidemiology 
In the past decade the rate of new TB cases had been falling by 2% worldwide (Figure 2) 
(Global tuberculosis report, 2013).  It is clear that stop TB target of halving TB prevalence in 
2015 as compared to 1990 was not achieved globally (Global tuberculosis report 2015). The 
American and western pacific regions already achieved this target a head of time. The South 
East Asia and Europe have achieved the target recently (Global tuberculosis report 2015; 
Global tuberculosis report 2013).    However, in African regions, the 2% reduction which was 
seen in the past decade was not good enough to achieve the Stop TB target though there is 
variability in performance among countries (Global tuberculosis report, 2015).  For instance, 
Uganda, Tanzania and Ethiopia have achieved all the three global targets whereas; South 
Africa, Kenya and Zimbabwe have achieved the incidence reduction only. To the contrary, in 
countries like Mozambique, Democratic Congo and Nigeria the reduction was not good enough 
to achieve any of the three global TB targets set for 2015 (Global tuberculosis report, 2015).  
 
 
Figure 2   line graph of a 24 years Global tuberculosis incidence, prevalence and mortality 
trends per 100000 ( Global tuberculosis reports, 1990- 2015) 
3.2. Epidemiology of TB in Ethiopia 
Tuberculosis is the third cause of death in Ethiopia next to pneumonia and HIV (Federal 
ministry of health, Health and health related indicators, 2014 
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http://www.cnhde.org.et/?page_id=19 ).  Ethiopia has been ranked as fourth from African and 
tenth from the world in relation to the number of TB cases occurred annually (Global 
tuberculosis report, 2015). The country is also one of the 27 MDR high burden countries in the 
world (Global tuberculosis report, 2015). Ethiopian national prevalence survey conducted in 
2010/2011 estimated the prevalence of TB as 277 per 100,000 (Kebede et al., 2014).  
Ever since the year 1990 the government of Ethiopia mobilized all of its efforts to fight TB 
through early detection and treatment strategy. There was a massive utilization of health 
extension program throughout the country in the past 20 years. As a result, significant success 
was recorded in achieving the target set by WHO to stop TB (Figure 3) (Global tuberculosis 
report, 2015).Currently, Ethiopia has adopted a new, more precise end TB strategy from WHO. 
This new strategy targeted to reduce the incidence of TB as low as 10/100,000 population by 
the year 2035 (World Health Organization, The end TB strategy, 2015. 
http://www.who.int/tb/End_TB_brochure.pdf ) 
 
Figure 3; Line graph of a 24 years trend of tuberculosis in Ethiopia (WHO report, 1990-2015) 
4. Factors that determine tuberclosis disease 
Tuberculosis is a complex disease that involves different interlinked factors. In most of the 
cases these factors works synergestically and the occurance of one factor possibly predisposes 
to the other. For the sake of simplicity in this dissertation we have categorised factors that 
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influence TB from transmission to disease into three categories. These are pathogen factor, 
host factor and environmental factors. 
4.1. Pathogen factor 
The pathogenecity of a micro organisms are usually associated with the presence of virulence 
factor (Kędzierska and Hayes, 2016). M.tuberculosis is one of highly evolved bacteria that 
learned to live inside its host by overcoming the challenges. The irony thing is that, there is no 
classical bacterial virulence factors such as toxin and pathogenecity island identified from 
M.tuberculosis  so far(Forrelland et al., 2013). However, Region of difference one (RD1) 
(Volkman et al., 2004: Guinn et al., 2004), Protein kinase G (Tiwari et al., 2009), 
Lipoarabinomannan (LAM) (Fukuda et al., 2013), the cord factor (trehalose 6,6′-dimycolate), 
(Harland et al., 2008) were described to be associated with pathogenecity of M.tuberculosis. 
Apart from these some lineages of M.tuberculosis are more virulence than the others. For 
instance Beijing lineage was described to be associated with MDR tuberculosis epidemics. 
Strains of this lineage have been proposed to possess selective advantages in comparison to 
strains from other MTBC lineagesattributed to an increased capacity to acquire drug resistance, 
linked to hypermutability(Ford et al., 2013) . 
4.2. Host factor including behavioral and social aspects 
Susceptible host is one of the three epidemiology triads that determine the occurrence of 
disease. According to published researches on tuberculosis several host factors has been 
mentioned to determine the occurrence of TB disease.  To mention some; genetic 
polymorphisms in TLR and HLA genes that affect host pathogen interaction or the strength of 
innate immune response (Fol et al., 2015), physiological factors like age and sex, nutritional 
factors, co-morbid and immune suppressive conditions such as diabetes and HIV (Hailu et al., 
2014; Amare et al., 20013;Jeon et al., 2008), and behavioral factors such as smoking and 
alcohol abuse  were well described in different studies (Ephrem et al., 2015;Wassie et al., 2014; 
Alavi-Naini et al., 2012). 
4.3. Environment and other factors 
Environmental factor which also includes the living condition and socio economic status is the 
other important factor for tuberculosis disease occurrence (Lacerda et al., 2014). TB is now 
becoming more of the problem of the poor (Marais et al., 2009). Most of the global tuberculosis 
burden is reported from low and middle income countries specifically from Africa and South 
East Asia (Global tuberculosis report, 2015). This part of the world is known by limited access 
for quality health service, extreme poverty, overcrowded living conditions and malnutrition 
(Marais et al., 2009).  
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Overcrowding is one of the most important factors to facilitate TB transmission (Marais et al., 
2009). The number of peoples living per single room, size of the room, the ventilation condition 
of the room and the length of time spent in the room are different aspects of overcrowding. 
There are also facilities which are naturally prompted overcrowding. Some of these are day 
care centers, orphanages, military camps, universities, refugee camps and prisons. Unless the 
design of the rooms, the size of the rooms and the number of person per room are well 
managed it is highly likely for such facilities to favor TB transmission especially in low and 
middle income countries. 
Prisons are one of the known overcrowded facilities which recently receiving attention globally. 
The global estimated number of people detained on any given day, is over 9 million (Dara et al., 
2009). In countries like Ethiopia, the buildings and health infrastructure available in prisons is 
very deprived. As a result the problem of infectious diseases including tuberculosis could be 
high in prison facility.  
5. Rationale  
Tuberculosis (TB) is a major health problem in prisons and its prevalence was reported to be 
multiple times higher compared to that of the general population. Conditions such as 
overcrowding, malnutrition and limited access to medical care which often exist in prisons 
increase the risk of reactivation, transmission and poor prognosis of tuberculosis disease 
among inmates (Baussano et al., 2010; Habeenzu et al., 2007) 
Several cross-sectional studies estimated the prevalence of TB in African prisons. Studies 
published from Cameroon, Zambia and Malawi reported relatively differing prevalence which 
was between 2.6 and 10 times higher than in the general population of the respective country 
(Banda et al., 2009;Habeenzu et al., 2007;Noeske et al., 2006). From Ethiopia, so far three 
studies were reported from 5 different prisons in Eastern Ethiopia, North Gondar zone and 
Gamo Gofa zone. The reported numbers for TB prevalence, 1,913, 1,482.3 and 629 TB cases 
per 100,000 inmates respectively, were comparable to that from other African settings (Zerdo et 
al., 2014;Moges et al., 2012;Abebe et al., 2011)   
Prisons are regulated but not closed systems, due to the numbers of people who constantly 
enter, leave and re-enter into them. Therefore, prison health is a critical part of public health as 
health problems within and outside prisons are interrelated (Aerts et al., 2006). Every 
successful TB control program also requires effective TB control in prisons and failure to control 
TB in prisons has the potential to disrupt community TB control programs (O’Grady et al., 
2011). Ethiopia is one of the 22 tuberculosis high burden countries with a recent TB prevalence 
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of 211 per 100,000 populations (Global tuberculosis report, 2014). According to the Ethiopian 
Human Right commission 2012 report, a total of 86,610 inmates were incarcerated in 119 
prisons in Ethiopia (The ethiopian Human right comission, 2012 
http://www.ehrc.org.et/LinkClick.aspx?fileticket=1uE7TO6QzbQ%3D&tabid=117). 
Despite this fact, relatively little attention has been given to assess the condition of TB in 
Ethiopian prisons in the past. Those 3 studies mentioned above (Zerdo et al., 2014;Moges et 
al., 2012;Abebe et al., 2011) were relatively small and limited to 3 areas of the country. Further 
more, to date, no molecular epidemiological studies have been carried out to decipher MTBC 
population structure and drug susceptibility patter in prisons in Ethiopia.  
6. Research questions and Objectives 
6.1. Research questions 
After understanding these existed knowledge gaps, the following research questions were 
asked. What is the magnitude of TB in prison? Does this magnitude is higher or lower than the 
reported population TB prevalence? What are the determinants of tuberculosis in prison? Is the 
population structure of MTBC isolates from prison differs from isolates from the community? 
What does the drug susceptibility pattern of MTBC isolates looks like? To answer these 
questions, this research was planned as part of my PhD aiming to contribute something for 
prison TB control effort of Ethiopia. 
6.2. Objective 
6.2.1. General objective  
To assess the magnitude of tuberculosis, risk factors, drug resistance patterns and MTBC 
population structure in Ethiopian prisons.  
6.2.2. Specific Objective 
 To determine the prevalence of tuberculosis in Ethiopian prisons 
 To identify possible risk factors for tuberculosis in prison. 
 To identify dominant strains/genotypes of M. tuberculosis in prisons 
 To determine first line drug susceptibility patterns of isolated  M. tuberculosis 
genotypes 
 To  determine the association between drug susceptibility and strain of M. 
tuberculosis 
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7. Methodology 
7.1. Study setting 
Ethiopia is administratively organized within nine regions and two federal cities. Among these, 
Oromia, Amhara and Southern Nations, Nationalities and Peoples Regional State (SNNPRS) 
are the three biggest regions with a total population of approximately 67,730,002 (more than 
80% of total Ethiopian population). Harari is the smallest regional state with a population of only 
210,000 (Central statistics Agency, 2012). Due to logistic reasons such as cooperation with 
investigators and accessibility from the study centre at Jimma University the participating 
prisons for this study were selected from Oromia, SNNPRS and Harari regional states (Please 
see publication  A for detail information).  
7.2. Sample size estimation 
A total of 13 zonal administrative level prisons were randomly selected by lottery method. 
Accordingly, seven out of 17 and five out of 13 prisons were drawn from Oromia and SNNPRS, 
respectively, while the only prison of Harari regional state was included in the study. By this 
approach, ca. 35% of the total prison population of the included regional states was 
represented in this study. For molecular epidemiology study all isolated bacteria from prison 
study and 100 strains from respective hospitals were included (Please see the methodologies 
of publication A and B attached in this document). 
7.3. Data and sample collection  
A cross sectional study was done from January 2013 to June 2015. Study activities were 
conducted in one prison after the other (Please see the methodology of publication A and B for 
detail explanation). 
7.4. Statistical analysis 
All data were recorded on standardized data collection forms. Data were double-entered in an 
excel data base. Analysis was done by STATA version 10. In the descriptive analysis, for 
categorical variables proportions with 95% confidence level and for continuous variables means 
with 95%CI were calculated. Univariable logistic regression analysis was conducted to analyze 
the association between individual risk factors TB-diagnosis/clustering; a p-value of <0.05 was 
considered as significant. Factors with significant association were used to build the final 
multivariable logistic regression model using a forward elimination approach. Likelihood ratio 
test was performed to confirm significant association of each risk factor with the outcome in 
multivariable regression model and to test for a linear trend for categorical variables. Almost all 
of the statistical analysis were done by the PhD candidate. Specifically,data entry, cleaning, 
descriptive analysis, Univariate analysis and Multivariate analysis by using STATA version 10 
16 
 
software. Furthermore, advanced logistic regression and molecular typing data was analyzed 
with the help of direct LMU supervisor and Borstel collaborators. 
8. Publications 
8.1. Brief summary of first publication 
The first paper was published in December 2015. The paper has mainly addressed the 
magnitude and risk factors of tuberculosis in Ethiopian prison. A total of 15 495 inmates 
incarcerated in 13 zonal prisons were screened and 765 participants who fulfilled the inclusion 
criteria were included. The study was a cross sectional study done from January 2013 to 
December 2013 on inmates incarcerated in 3 regional states. The prevalence and risk factors 
were determined and clearly presented in the result section of the attached paper. One 
interesting finding was the linear relation between TB prevalence in prison and the location of 
the prison from the central Ethiopia Addis Ababa which indicated the need to address TB in 
remote part of the country. All the major findings were also discussed and interpreted in 
comparison with other previous study reports done in Ethiopia or elsewhere to give broader 
horizon for the reader. Finally conclusion and recommendations were forwarded for stake 
holders working in TB prison in Ethiopia in particular for better control of the disease and global 
scientific communities working in tuberculosis in general. For detail information please see the 
attached full text in this paper or visit Ali et al., 2014 from plos one 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671540/pdf/pone.0144040.pdf ) 
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8.2. Brief summary of second publication 
In this paper, MTBC population structure, transmission dynamics and drug susceptibility pattern 
of isolates from prisons and communities of southern, southwest and eastern part of Ethiopia 
were reported using combined spoligotyping and MIRU-VNTR typing methods. A total of 127 
strains collected from Oroimia, SNNRS, Somali, Dire Dawa and Harari regional states. These 
strains were transported to German, Borstel for molecular finger printing and DST. 
Diverse population structure of MTBC with no difference between the prison and community 
isolates were observed as indicated on radial UPGMA tree based on MIRU-VNTR analysis. 
Ethiopian_H37Rv like genotype was the dominant strain seen in both prison and community 
isolates. Isolates from some regional states showed higher clustering rate than others. For 
instance, isolates from Somali regional state are more clustered than others. This finding is very 
important finding due to the fact that TB is still actively transmitted more in this regional state. 
The drug susceptibility patterns of the isolates were the same among prison and community 
isolates.  
A total of 24.77% of the isolates were resistance against at least one first line anti TB drugs. 
Furthermore, the MDR rate was found out to be 2.47% on strains isolated from community. 
Drug resistance was equally distributed among different genotypes isolated from prison or 
communities. The finding was discussed and interpreted in detail in line with available 
literatures and current knowledge regarding population structure and DST of MTB.  
Finally conclusions and recommendations were forwarded to indicate the future direction of TB 
control or research in Ethiopia. Please read the attached full text article or visit 
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-2041-x  for further detail 
information. 
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9.  Limitations of the study 
This research has some limitations. Due to adoption of more stringent WHO recommended TB 
in prison screening approach and logistics constraints to employ chest x-ray, the observed 
prevalence of TB in Prison might be under estimated. Furthermore, relatively low number of M. 
tuberculosis strains isolated from prison might have influenced the clustering and transmission 
dynamics of M.tuberculosis in prison. Apart from these, the thesis is the first well organized, 
structured and representative research done in Ethiopia prisons so far. It surfaced out the 
magnitude, distribution, determinants and lineage diversity of M.tuberculosis in Ethiopia prison. 
It also has indicated the areas of priorities and strategies that would be used for TB control in 
Ethiopian prison and the community as well. 
10. Conclusion and recommendation 
The average TB prevalence in prison inmates is twice higher than the prevalence in the general 
population and a great variability of prevalence among different prisons existed. This variability 
and the higher TB burden in prisons located far from the capital suggest that the national TB 
control measures are either not similarly implemented in the different prisons or have a differing 
impact on TB-control in specific prison environments or study populations. This needs further 
attention and future studies should focus on risk factors related to the individual but also on 
factors inherent to the general population and the prison environment including the functioning 
of TB control strategies.  
Tuberculosis in communities and prisons is caused by a variety of MTBC lineages with 
predominance of local Ethiopian lineages. The observed overall clustering rate is low, indicating 
reactivation of a remote infection rather than new transmission. The increasing prevalence of 
MDR is alarming. These findings suggest the need for new approaches to address latent 
tuberculosis infection and to control MDR-TB in Ethiopia.  
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